Influenza vaccine (adjuvanted quadrivalent, GSK2584786A)

GSK2584786A is an investigational adjuvanted quadrivalent inactivated influenza vaccine developed by GSK. It is formulated as an emulsion for intramuscular injection and contains split virion antigens from four different strains of the influenza virus, including A/California/7/2009 (H1N1)-like. The formulation includes the AS03 adjuvant system to enhance immunogenicity. The primary indication was prevention of seasonal and pandemic influenza infection, particularly in pediatric populations. Clinical development reached Phase 2 but was discontinued before approval[1][3][4][7].

Brand names

FLU D-QIV-AS03

Other names

adjuvanted quadrivalent influenza vaccineFLU D-QIV-AS03 quadrivalent inactivated influenza vaccine adjuvanted with AS03DFLU D-QIV-AS03 quadrivalent inactivated influenza vaccine adjuvanted with AS03E